Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference

Preventive Medicine

Volumn 98, Issue , 2017, Pages 21-30

  Giorgi Rossi, Paolo ^a,b   Carozzi, Francesca ^c   Federici, Antonio ^d   Ronco, Guglielmo ^e   Zappa, Marco ^c   Franceschi, Silvia ^f   Barca, Alessandra ^g   Barzon, Luisa ^g   Baussano, Iacopo ^h   Berliri, Carla ^g   Bonanni, Paolo ^g   Boselli, Fausto ^g   Boveri, Sara ^g   Buonaguro, Franco Maria ^g   Burroni, Elena ^g   Carillo, Giuseppe ⁱ   Carretta, Elisa ^g   Chini, Francesco ^g   Confortini, Massimo ^g   Dalla Palma, Paolo ^g   Declich, Silvia ^g   Del Mistro, Annarosa ^g   Del Sole, Anna Maria ^j   Ferretti, Stefano ^g   Gabutti, Giovanni ^g   Gargiulo, Franco ^g   Giambi, Cristina ^g   Iannazzo, Stefania ^g   Iossa, Anna ^g   Levi, Miriam ^g   Lillo, Flavia ^k   Maccalini, Vincenzo ^l   Mangia, Maria Luisa ^g   Mariani, Luciano ^g   Naldoni, Carlo ^g   Ocello, Cristina ^g   Paci, Eugenio ^g   Pellegrini, Antonella ^g   Perino, Antonio ^g   Pezzarossi, Annamaria ^g   Pilia, Massimo ^g   Placidi, Antonio ^g   Pompa, Maria Grazia ^g   Russo, Francesca ^m   Sandri, Maria Teresa ^g   Sani, Cristina ^g   Scalisi, Aurora ^g   Schiboni, Maria Luisa ^g   Segnan, Nereo ^g   Sideri, Mario ^g   Spinillo, Arsenio ^g   Taddei, Gian Luigi ^g   Tornesello, Maria Lina ^g   Venturelli, Francesco ^g   Vocaturo, Amina ^g   Zorzi, Manuel ^g   more..

^a PATHOLOGY UNIT   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c ISPO   (Italy)

^d MINISTRY OF HEALTH   (Italy)

^e CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^g International Agency for Research on Cancer ^*  (Italy)

^h NONE   (Italy)

ⁱ Regional Reference Laboratory for influenza   (Italy)

^j NONE   (Italy)

^k Respiratory Diseases Unit Hospital of Sestri Levante   (Italy)

^l Abruzzo Lazio and Molise National Park (PNALM)   (Italy)

^m Regional Reference Laboratory for influenza   (Italy)

more..

Author keywords

Human Papillomavirus DNA Test; Mass screening; Papillomavirus Vaccines; Primary Prevention; Secondary Prevention; Uterine Cervical Neoplasms; Women's Health Services

Indexed keywords

WART VIRUS VACCINE;

CANCER SCREENING; CLINICAL PROTOCOL; CLINICAL RESEARCH; COHORT ANALYSIS; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; EVIDENCE BASED PRACTICE; HERD IMMUNITY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; ITALIAN (CITIZEN); MASS SCREENING; MEDICAL SOCIETY; PAPILLOMAVIRUS INFECTION; PRIMARY PREVENTION; RESCREENING; SECONDARY PREVENTION; UTERINE CERVIX CANCER; VACCINATION; CONSENSUS; EARLY CANCER DIAGNOSIS; FEMALE; HEALTH SERVICE; ITALY; UTERINE CERVICAL NEOPLASMS;

CONSENSUS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; ITALY; PAPILLOMAVIRUS VACCINES; PRIMARY PREVENTION; SECONDARY PREVENTION; UTERINE CERVICAL NEOPLASMS; VACCINATION; WOMEN'S HEALTH SERVICES;

EID: 85011419307     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2016.11.020     Document Type: Article

References (87)

1. Agarossi, A., Ferrazzi, E., Parazzini, F., Perno, C.F., Ghisoni, L., Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy. J. Med. Virol. 81 (2009), 529–535 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/19152401.
2. AIRTUM, ITACAN. ([cited 2015 Jul 9]; (Available from) http://itacan.ispo.toscana.it/italian/itacan.htm, 2015.
3. Australian Institute of Health and Welfare, Cervical screening in Australia 2010–2011. National Cervical Screening Program. 2013 ([cited 2014 Jun 4]; Available from) http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id = 60129543399).
4. Baldur-Felskov, B., Dehlendorff, C., Junge, J., Munk, C., Kjaer, S., Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control 25 (2014), 915–922 (Available from) https://www.ncbi.nlm.nih.gov/pubmed/24797870.
5. Brotherton, J.M.L., Saville, A.M., May, C.L., Chappell, G., Gertig, D.M., Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia. Cancer Causes Control 26 (2015), 953–954 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/25804857.
6. Brown, P., Brunnhuber, K., Chalkidou, K., Chalmers, I., Clarke, M., Fenton, M., Forbes, C., Glanville, J., Hicks, N.J., Moody, J., Twaddle, S., Timimi, H., How to formulate research recommendations. BMJ 333 (2006), 804–806, 10.1136/bmj.38987.492014.94 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/17038740.
7. Bruni, L., Barrionuevo-Rosas, L., Albero, G., Aldea, M., Serrano, B., Valencia, S., Brotons, M., Mena, M., Cosano, R., Muñoz, J., Bosch, F.X., de Sanjose, S., et al. Human papillomavirus and related diseases in Europe. Summary Report 2015-04-08, 2015 ([cited 2015 Jul 9];Available from) http://www.hpvcentre.net/statistics/reports/XEX.pdf.
8. Capra, G., Giovannelli, L., Bellavia, C., Migliore, M.C., Caleca, M.P., Perino, A., Ammatuna, P., HPV genotype prevalence in cytologically abnormal cervical samples from women living in south Italy. Virus Res. 133 (2008), 195–200 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/18282628.
9. Carozzi, F.M., Tornesello, M.L., Burroni, E., Loquercio, G., Carillo, G., Angeloni, C., Scalisi, A., Macis, R., Chini, F., Buonaguro, F.M., Giorgi Rossi, P., HPV Prevalence Italian Working Group. Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev. A Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol. 19 (2010), 2389–2400 http://www.ncbi.nlm.nih.gov/pubmed/20826836 10.1158/1055-9965.EPI-10-0131 (Available from).
10. Castle, P.E., Rodríguez, A.C., Burk, R.D., Herrero, R., Wacholder, S., Alfaro, M., Morales, J., Guillen, D., Sherman, M.E., Solomon, D., Schiffman, M., Proyecto Epidemiológico Guanacaste (PEG) Group. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ, 339, 2009, b2569 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/19638649 10.1136/bmj.b2569.
11. Castle, P.E., Stoler, M.H., Wright, T.C., Sharma, A., Wright, T.L., Behrens, C.M., Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 12 (2011), 880–890 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/21865084.
12. Chow, E.P.F., Read, T.R.H., Wigan, R., Donovan, B., Chen, M.Y., Bradshaw, C.S., Fairley, C.K., Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex. Transm. Infect. 91 (2015), 214–219 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/25305210.
13. Ciotti, M., Paba, P., Bonifacio, D., Di Bonito, L., Benedetto, A., Favalli, C., Single or multiple HPV types in cervical cancer and associated metastases. Oncol. Rep. 15 (2006), 143–148 (Available from). http://www.ncbi.nlm.nih.gov/pubmed/16328047.
14. Clifford, G.M., Smith, J.S., Aguado, T., Franceschi, S., Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br. J. Cancer 89 (2003), 101–105 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/12838308.
15. Clifford, G.M., Smith, J.S., Plummer, M., Muñoz, N., Franceschi, S., Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88 (2003), 63–73 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/12556961.
16. CNESPS, ISS, Survey PASSI 2011–14. ([cited 2015 Jul 9]; Available from) http://www.epicentro.iss.it/passi/dati/ScreeningCervicale.asp, 2015.
17. CNESPS, ISS, Stato di avanzamento della campagna vaccinale per l'HPV: dati di copertura vaccinale al 31/12/2014 – Rapporto semestrale (dati aggiornati di tutte le Regioni). ([cited 2015 Jul 9]; Available from) http://www.epicentro.iss.it/temi/vaccinazioni/dati_Ita.asp?tab-container-1=tab113, 2015.
18. Commissione Oncologica Nazionale. Proposte operative in tema di prevenzione secondaria del cervico-carcinoma uterino. In: “Linee guida elaborate dalla Commissione Oncologica Nazionale, in applicazione di quanto previsto dal Piano Sanitario Nazionale per il triennio 1994–96, relativo all'a. 1996.” (Gazzetta Ufficiale n.127 del 1-6-1996 - Suppl. Ordinario n. 88. Available from http://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario;jsessionid=rO6j509WttetHl7DfPpZkA__.ntc-as5-guri2b?atto.dataPubblicazioneGazzetta=1996-06-01&atto.codiceRedazionale=096A3281&elenco30giorni=false;).
19. CSS, Piano Nazionale Prevenzione Vaccinale 2016–2018. (Available from) http://www.quotidianosanita.it/allegati/allegato1955037.pdf, 2015.
20. De Carvalho, N., Teixeira, J., Roteli-Martins, C.M., Naud, P., De Borba, P., Zahaf, T., Sanchez, N., Schuind, A., Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 28 (2010), 6247–6255 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/20643092.
21. de Sanjose, S., Quint, W.G., Alemany, L., Geraets, D.T., Klaustermeier, J.E., Lloveras, B., Tous, S., Felix, A., Bravo, L.E., Shin, H.-R., Vallejos, C.S., de Ruiz, P.A., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 11 (2010), 1048–1056 http://www.ncbi.nlm.nih.gov/pubmed/20952254 10.1016/S1470-2045(10)70230-8 (Available from).
22. de Sanjose, S., Alemany, L., Tous, S., Bosch, F.X., HPV RIS TT Study Group, HPV types in early-onset cervical cancer – Authors’ reply. Lancet Oncol. 12 (2011), 117–118.
23. Del Mistro, A., Salamanca, H.F., Trevisan, R., Bertorelle, R., Parenti, A., Bonoldi, E., Zambon, P., Minucci, D., Human papillomavirus typing of invasive cervical cancers in Italy. Infect. Agent Cancer, 1, 2006, 9 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/17192187.
24. Deleré, Y., Wichmann, O., Klug, S.J., van der Sande, M., Terhardt, M., Zepp, F., Harder, T., The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis. Dtsch. Arztebl. Int. 111 (2014), 584–591 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/25249360.
25. Dobson, S.R.M., McNeil, S., Dionne, M., Dawar, M., Ogilvie, G., Krajden, M., Sauvageau, C., Scheifele, D.W., Kollmann, T.R., Halperin, S.A., Langley, J.M., Bettinger, J.A., et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 309 (2013), 1793–1802 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/23632723.
26. Donati, S., Giambi, C., Declich, S., Salmaso, S., Filia, A., Ciofi degli Atti, M.L., Alibrandi, M.P., Brezzi, S., Carozzi, F., Collina, N., Franchi, D., Lattanzi, A., et al. Knowledge, attitude and practice in primary and secondary cervical cancer prevention among young adult Italian women. Vaccine 30 (2012), 2075–2082 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/22300719.
27. Drolet, M., Bénard, É., Boily, M.-C., Ali, H., Baandrup, L., Bauer, H., Beddows, S., Brisson, J., Brotherton, J.M.L., Cummings, T., Donovan, B., Fairley, C.K., et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. 15 (2015), 565–580 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/25744474 10.1016/S1473-3099(14)71073-4.
28. Ferris, D., Samakoses, R., Block, S.L., Lazcano-Ponce, E., Restrepo, J.A., Reisinger, K.S., Mehlsen, J., Chatterjee, A., Iversen, O.-E., Sings, H.L., Shou, Q., Sausser, T.A., et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics 134 (2014), e657–e665 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/25136050.
29. Franco, E.L., Mahmud, S.M., Tota, J., Ferenczy, A., Coutlée, F., The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch. Med. Res. 40 (2009), 478–485 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/19853188.
30. Gargiulo, F., De Francesco, M.A., Schreiber, C., Ciravolo, G., Salinaro, F., Valloncini, B., Manca, N., Prevalence and distribution of single and multiple HPV infections in cytologically abnormal cervical samples from Italian women. Virus Res. 125 (2007), 176–182 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/17257705.
31. Garzetti, G.G., Ciavattini, A., Lucarini, G., Goteri, G., Menso, S., De Nictolis, M., Romanini, C., Biagini, G., The role of human papillomavirus DNAs in cervical carcinoma and risk of lymph node metastasis: association with 72-kilodalton metalloproteinase immunostaining. Cancer 82 (1998), 886–892 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/9486578.
32. Giambi, C., Stato di avanzamento della campagna vaccinale per l'HPV: dati di copertura vaccinale al 31/12/2014 - Rapporto semestrale (dati aggiornati di tutte le Regioni). ([cited 2015 Jul 9]; Available from) http://www.epicentro.iss.it/problemi/hpv/pdf/Aggiornamento_HPV_31122014Completo.pdf, 2014.
33. Giambi, C., Del Manso, M., De Mei, B., D'Ancona, F., Giovanelli, I., Cattaneo, C., Possenti, V., Declich, S., Gruppo di lavoro VALORE. Progetto VALORE (VAlutazione LOcale e REgionale delle campagne di vaccinazione contro l'HPV): favorire l'adesione consapevole alla vaccinazione. ([cited 2015 Jul 9]; Available from) http://www.iss.it/binary/publ/cont/13_47_web.pdf, 2013.
34. Giorgi Rossi, P., Bisanzi, S., Paganini, I., Di Iasi, A., Angeloni, C., Scalisi, A., Macis, R., Pini, M.T., Chini, F., Carozzi, F.M., HPV Prevalence Italian Working Group. Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study. BMC Infect. Dis., 10, 2010, 214 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/20646310.
35. Giorgi Rossi, P., Sideri, M., Carozzi, F.M., Vocaturo, A., Buonaguro, F.M., Tornesello, M.L., Burroni, E., Mariani, L., Boveri, S., Zaffina, L.M., Chini, F., HPV Prevalence Italian Working Group. HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies. Infect. Agent Cancer, 7, 2012, 26 http://www.ncbi.nlm.nih.gov/pubmed/23110797 10.1186/1750-9378-7-26 (Available from).
36. Giorgi Rossi, P., Chini, F., Borgia, P., Guasticchi, G., Carozzi, F.M., Confortini, M., Angeloni, C., Buzzoni, C., Buonaguro, F.M., Gruppo di lavoro HPV Prevalenza, Human Papilloma Virus (HPV), cervical cancer incidence and screening uptake: differences among Northern, Central and Southern Italy. Epidemiol. Prev. 36 (2012), 108–119 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/22706361.
37. Giorgi Rossi, P., Caroli, S., Mancini, S., de’ Bianchi, P.S., Finarelli, A.C., Naldoni, C., Bucchi, L., FFE-R cervical cancer screening and pathology registry group. Screening history of cervical cancers in Emilia-Romagna, Italy: defining priorities to improve cervical cancer screening. Eur. J. Cancer Prev. 24 (2015), 128–134 https://www.ncbi.nlm.nih.gov/pubmed/24787379 10.1097/CEJ.0000000000000035 (Available at).
38. GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski, B., de Borba, P.C., Naud, P.S., Roteli-Martins, C.M., De Carvalho, N.S., Teixeira, J.C., Aoki, F., Ramjattan, B., Shier, R.M., Somani, R., Barbier, S., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374 (2009), 1975–1985 ((London, England) Available from) http://www.ncbi.nlm.nih.gov/pubmed/19962185.
39. Guan, P., Howell-Jones, R., Li, N., Bruni, L., de Sanjosé, S., Franceschi, S., Clifford, G.M., Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int. J. Cancer 131 (2012), 2349–2359 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/22323075.
40. Guan, P., Clifford, G.M., Franceschi, S., Human papillomavirus types in glandular lesions of the cervix: a meta-analysis of published studies. Int. J. Cancer 132 (2013), 248–250 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/22684765.
41. Harper, D.M., Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15–25 years of age. Gynecol. Oncol. 110 (2008), S11–S17 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/18649932.
42. Intesa tra il Governo, le Regioni e le Province autonome di Trento e Bolzano, Piano Nazionale Prevenzione Vaccinale (PNPV) 2012–2014. Intesa ai sensi dell'articolo 8, comma 6, della legge 5 giugno 2003, n°131. http://www.statoregioni.it/Documenti/DOC_035260_54csrpunto4.pdf, 2015 ([cited 2015 Jul 9]; Available from).
43. Intesa tra il Governo le Regioni e le Provincie autonome, Strategie per l'offerta attiva del vaccino contro l'infezione da HPV in Italia. ([cited 2015 Jul 9]; Available from) http://www.statoregioni.it/Documenti/DOC_016696_264cse.pdf, 2007.
44. Joura, E.A., Giuliano, A.R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E.D., Ngan, Y., Petersen, L.K., Lazcano-Ponce, E., Pitisuttithum, P., Restrepo, J.A., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N. Engl. J. Med. 372 (2015), 711–723 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/25693011.
45. Kavanagh, K., Pollock, K.G.J., Potts, A., Love, J., Cuschieri, K., Cubie, H., Robertson, C., Donaghy, M., Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br. J. Cancer 110 (2014), 2804–2811 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/24736582.
46. Khan, M.J., Castle, P.E., Lorincz, A.T., Wacholder, S., Sherman, M., Scott, D.R., Rush, B.B., Glass, A.G., Schiffman, M., The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97 (2005), 1072–1079 http://www.ncbi.nlm.nih.gov/pubmed/16030305 10.1093/jnci/dji187 (Available from).
47. Kjær, S.K., Frederiksen, K., Munk, C., Iftner, T., Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J. Natl. Cancer Inst. 102 (2010), 1478–1488 http://www.ncbi.nlm.nih.gov/pubmed/20841605 10.1093/jnci/djq356 (Available from).
48. Kreimer, A.R., Struyf, F., Del Rosario-Raymundo, M.R., Hildesheim, A., Skinner, S.R., Wacholder, S., Garland, S.M., Herrero, R., David, M.-P., Wheeler, C.M., Costa Rica Vaccine Trial and PATRICIA study groups. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol. 16 (2015), 775–786 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/26071347.
49. Laconi, S., Greco, M., Milia, G., Pellegrini-Bettoli, P., Pani, P., Laconi, E., Rais, M., Simultaneous detection and typing of human papillomavirus in cervical biopsies using PCR-reverse hybridization. Pathologica 92 (2000), 524–529 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/11234303.
50. Lehtinen, M., Dillner, J., Clinical trials of human papillomavirus vaccines and beyond. Nat. Rev. Clin. Oncol. 10 (2013), 400–410 http://www.ncbi.nlm.nih.gov/pubmed/23736648 (Available from).
51. Li, N., Franceschi, S., Howell-Jones, R., Snijders, P.J.F., Clifford, G.M., Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int. J. Cancer 128 (2011), 927–935 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/20473886.
52. Lillo, F., Galli, L., Lodini, S., Taccagni, G., Ferrari, A., Origoni, M., Extralesional detection and load of human papillomavirus DNA: a possible marker of preclinical tumor spread in cervical cancer. J. Low. Genit. Tract. Dis. 12 (2008), 204–209 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/18596462.
53. Lipsitch, M., Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg. Infect. Dis. 5 (1999), 336–345 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/10341170.
54. Lu, B., Kumar, A., Castellsagué, X., Giuliano, A.R., Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect. Dis., 11, 2011, 13 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/21226933.
55. Luna, J., Plata, M., Gonzalez, M., Correa, A., Maldonado, I., Nossa, C., Radley, D., Vuocolo, S., Haupt, R.M., Saah, A., Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women. PLoS One, 8, 2013, e83431 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/24391768.
56. Mariani, L., Monfulleda, N., Alemany, L., Vizza, E., Marandino, F., Vocaturo, A., Benevolo, M., Quirós, B., Lloveras, B., Klaustermeier, J.E., Quint, W., de Sanjosé, S., et al. Human papillomavirus prevalence and type-specific relative contribution in invasive cervical cancer specimens from Italy. BMC Cancer, 10, 2010, 259 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/20525370.
57. Naud, P.S., Roteli-Martins, C.M., De Carvalho, N.S., Teixeira, J.C., de Borba, P.C., Sanchez, N., Zahaf, T., Catteau, G., Geeraerts, B., Descamps, D., Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum. Vaccin. Immunother. 10 (2014), 2147–2162 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/25424918.
58. Olsson, S.-E., Villa, L.L., Costa, R.L.R., Petta, C.A., Andrade, R.P., Malm, C., Iversen, O.-E., Høye, J., Steinwall, M., Riis-Johannessen, G., Andersson-Ellstrom, A., Elfgren, K., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25 (2007), 4931–4939 http://www.ncbi.nlm.nih.gov/pubmed/17499406 10.1016/j.vaccine.2007.03.049 (Available from).
59. ONS, Programmi di screening in Italia 2014. ([cited 2015 Jul 9]; Available from) http://www.osservatorionazionalescreening.it/sites/default/files/allegati/screening_matite_2.pdf#overlay-context=content/i-rapporti-brevi-dell%25E2%2580%2599ons, 2015.
60. Paavonen, J., Jenkins, D., Bosch, F.X., Naud, P., Salmerón, J., Wheeler, C.M., Chow, S.-N., Apter, D.L., Kitchener, H.C., Castellsague, X., de Carvalho, N.S., Skinner, S.R., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007), 2161–2170 ((London, England) Available from) http://www.ncbi.nlm.nih.gov/pubmed/17602732.
61. Palmroth, J., Merikukka, M., Paavonen, J., Apter, D., Eriksson, T., Natunen, K., Dubin, G., Lehtinen, M., Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination. Int. J. Cancer 131 (2012), 2832–2838 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/22492244.
62. Pollock, K.G.J., Kavanagh, K., Potts, A., Love, J., Cuschieri, K., Cubie, H., Robertson, C., Cruickshank, M., Palmer, T.J., Nicoll, S., Donaghy, M., et al. Br. J. Cancer 111 (2014), 1824–1830 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/25180766.
63. Rolla, M., Berretta, R., Patrelli, T.S., Merisio, C., Gramellini, D., Fadda, G.M., Bacchi Modena, A., Nardelli, G.B., A perspective study on correlation between HPV DNA and lymph nodes in surgically treated cervical carcinoma patients. Preliminary data. Eur. J. Gynaecol. Oncol. 30 (2009), 557–561 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/19899415.
64. Romanowski, B., Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum. Vaccin. 7 (2011), 161–169 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/21307652.
65. Ronco, G., Biggeri, A., Confortini, M., Naldoni, C., Segnan, N., Sideri, M., Zappa, M., Zorzi, M., Calvia, M., Accetta, G., Giordano, L., Cogo, C., et al. Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors. Epidemiol. Prev. 36 (2012), e1–72 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/22828243.
66. Ronco, G., Dillner, J., Elfström, K.M., Tunesi, S., Snijders, P.J.F., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., Berkhof, J., Peto, J., et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383 (2014), 524–532 (London, England) http://www.ncbi.nlm.nih.gov/pubmed/24192252 10.1016/S0140-6736(13)62218-7 (Available from).
67. Roteli-Martins, C.M., Naud, P., De Borba, P., Teixeira, J.C., De Carvalho, N.S., Zahaf, T., Sanchez, N., Geeraerts, B., Descamps, D., Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum. Vaccin. Immunother. 8 (2012), 390–397 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/22327492.
68. Sandø, N., Kofoed, K., Zachariae, C., Fouchard, J., A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women—an ecological study. Acta Derm. Venereol. 94 (2014), 288–292 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/24150529.
69. Sandri, M.T., Riggio, D., Salvatici, M., Passerini, R., Zorzino, L., Boveri, S., Radice, D., Spolti, N., Sideri, M., Typing of human papillomavirus in women with cervical lesions: prevalence and distribution of different genotypes. J. Med. Virol. 81 (2009), 271–277 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/19107962.
70. Schiffman, M., Glass, A.G., Wentzensen, N., Rush, B.B., Castle, P.E., Scott, D.R., Buckland, J., Sherman, M.E., Rydzak, G., Kirk, P., Lorincz, A.T., Wacholder, S., et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev. A Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol. 20 (2011), 1398–1409 http://www.ncbi.nlm.nih.gov/pubmed/21602310 10.1158/1055-9965 (Available from).
71. Schwarz, T., Spaczynski, M., Kaufmann, A., Wysocki, J., Gałaj, A., Schulze, K., Suryakiran, P., Thomas, F., Descamps, D., Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study. BJOG Int J Obstet Gynaecol 122 (2015), 107–118 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/25208608.
72. Serraino, D., Gini, A., Taborelli, M., Ronco, G., Giorgi-Rossi, P., Zappa, M., Crocetti, E., Franzo, A., Falcini, F., Visioli, C.B., Stracci, F., Zorzi, M., et al. Changes in cervical cancer incidence following the introduction of organized screening in Italy. Prev. Med. 75 (2015), 56–63 http://www.ncbi.nlm.nih.gov/pubmed/25818232 10.1016/j.ypmed.2015.01.034 ((Baltim) Available from).
73. Sideri, M., Cristoforoni, P., Casadio, C., Boveri, S., Igidbashian, S., Schmitt, M., Gheit, T., Tommasino, M., Distribution of human papillomavirus genotypes in invasive cervical cancer in Italy: a representative, single institution case series. Vaccine 27:Suppl. 1 (2009), A30–A33 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/19480958.
74. Smith, J.S., Lindsay, L., Hoots, B., Keys, J., Franceschi, S., Winer, R., Clifford, G.M., Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121 (2007), 621–632 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/17405118.
75. Spinillo, A., Gardella, B., Roccio, M., Alberizzi, P., Silini, E.M., Dal, B.B., Untypable human papillomavirus infection and risk of cervical intraepithelial neoplasia among women with abnormal cervical cytology. J. Med. Virol. 86 (2014), 1145–1152 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/24692002.
76. Tabrizi, S.N., Brotherton, J.M.L., Kaldor, J.M., Skinner, S.R., Cummins, E., Liu, B., Bateson, D., McNamee, K., Garefalakis, M., Garland, S.M., Fall in human papillomavirus prevalence following a national vaccination program. J. Infect. Dis. 206 (2012), 1645–1651 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/23087430.
77. The FUTURE II Study Group, Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356 (2007), 1915–1927 ([cited 2015 Oct 10]Available from) 10.1056/NEJMoa061741.
78. Thomsen, L.T., Frederiksen, K., Munk, C., Junge, J., Iftner, T., Kjaer, S.K., Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology. Int. J. Cancer 137 (2015), 193–203 http://www.ncbi.nlm.nih.gov/pubmed/25471319 10.1002/ijc.29374 (Available from).
79. Tornesello, M.L., Duraturo, M.L., Botti, G., Greggi, S., Piccoli, R., De Palo, G., Montella, M., Buonaguro, L., Buonaguro, F.M., Italian, H.P.V., Working Group. Prevalence of alpha-papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population. J. Med. Virol. 78 (2006), 1663–1672 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/17063505.
80. Tornesello, M.L., Losito, S., Benincasa, G., Fulciniti, F., Botti, G., Greggi, S., Buonaguro, L., Buonaguro, F.M., Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecol. Oncol. 121 (2011), 32–42 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/21211829.
81. Tota, J., Mahmud, S.M., Ferenczy, A., Coutlée, F., Franco, E.L., Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era. Sex. Health 7 (2010), 376–382 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/20719230.
82. Venturoli, S., Ambretti, S., Cricca, M., Leo, E., Costa, S., Musiani, M., Zerbini, M., Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment. J. Med. Virol. 80 (2008), 1434–1440 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/18551620.
83. Villa, L.L., Costa, R.L.R., Petta, C.A., Andrade, R.P., Paavonen, J., Iversen, O.-E., Olsson, S.-E., Høye, J., Steinwall, M., Riis-Johannessen, G., Andersson-Ellstrom, A., Elfgren, K., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer 95 (2006), 1459–1466 http://www.ncbi.nlm.nih.gov/pubmed/17117182 10.1038/sj.bjc.6603469 (Available from).
84. Voglino, G., Poso, F., Privitera, S., Parisio, F., Ghiringhello, B., Gordini, G., Chiara, G., Massobrio, M., Fessia, L., The role of human papillomavirus in cyto-histological practice: distribution and prevalenceof hig-risk strains (16, 18, 31, 33, and 35) in intraepithelial lesions and neoplasia of the uterine cervix. Pathologica 92 (2000), 516–523 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/11234302.
85. von Karsa, L., Arbyn, M., De Vuyst, H., Dillner, J., Dillner, L., Franceschi, S., Patnick, J., Ronco, G., Segnan, N., Suonio, E., Törnberg, S., Anttila, A., European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 1 (2015), 22–31 [cited 2015 Dec 29] Available from) http://www.sciencedirect.com/science/article/pii/S2405852115000129.
86. WHO/RHR, Preparing for the Introduction of HPV Vaccines: Policy and Programme Guidance for Countries. ([cited 2015 Jul 9];Available from) http://www.who.int/reproductivehealth/publications/cancers/RHR_06.11/en/, 2006.
87. Zerbini, M., Venturoli, S., Cricca, M., Gallinella, G., De Simone, P., Costa, S., Santini, D., Musiani, M., Distribution and viral load of type specific HPVs in different cervical lesions as detected by PCR-ELISA. J. Clin. Pathol. 54 (2001), 377–380 (Available from) http://www.ncbi.nlm.nih.gov/pubmed/11328837.